Our intranasal delivery system will be an exciting alternative to epinephrine auto-injectors, providing patients with a needle-free option that is easy to use, portable, and affordable. With a recent $26.72M Venture Round investment on 10th May 2023, Bryn Pharma is making significant strides in the Health Care and Pharmaceutical industries. The company's innovative approach and commitment to empowering patients at risk for anaphylaxis position it as a compelling investment opportunity in the healthcare sector.
Bryn Pharma
We are creating a better way to empower patients at risk for anaphylaxis
Founded 2016
17 employees
Venture round
Total: $125.19M
Health Care, Pharmaceutical
General Information
Company Name
Bryn Pharma
Founded Year
2016
Founders / Decision Makers
Employees
17
Industries
Health Care, Pharmaceutical
Funding Stage
Venture round
BounceWatch is an independent company data service, not affiliated with Bryn Pharma. To contact Bryn Pharma, visit brynpharma.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Bryn Pharma compare?
A PDF of Bryn Pharma and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Bryn Pharma soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
Discover More
About Bryn Pharma
Business keywords: pharmaceuticals, anaphylaxis, intranasal delivery system, epinephrine, allergy products, patient empowerment, innovation, needle-free technology, portable medical devices
Funding Rounds & Investors (7)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Venture Round | $26.72M | - |
|
10 May 2023 |
| Venture Round | $43.51M | 3 |
|
19 Jul 2021 |
| Venture Round | $11.00M | 1 |
|
05 Aug 2020 |
| Series A | Undisclosed | - |
|
01 Feb 2020 |
| Venture Round | $17.50M | - |
|
24 Oct 2019 |
| Venture Round | $17.20M | - |
|
25 Feb 2019 |
| Venture Round | $9.25M | - |
|
16 Jul 2018 |
Bryn Pharma Alternatives & Competitors
View All Alternatives
Bryn Pharma vs
ARS Pharmaceuticals, Inc.
United States
Revolutionizing treatment for severe allergic reactions with the development of a needle-free epinep...
Merged
171 employees
Biopharma, Health Care
Bryn Pharma vs
Windgap Medical, Inc.
United States
Injecting simplicity into complex drug delivery
Series B
19 employees
Biotechnology, Health Care
Bryn Pharma vs
Portal Instruments
United States
Connected, Reusable Drug Delivery
22 employees
Health Care, Medical Devices
FAQ About Bryn Pharma
We are creating a better way to empower patients at risk for anaphylaxis
Bryn Pharma was founded in 2016.
Bryn Pharma operates in Health Care and Pharmaceutical. Its work centres on pharmaceuticals, anaphylaxis, intranasal delivery system and epinephrine.
Bryn Pharma has approximately 17 employees.
Bryn Pharma has completed 7 funding rounds, raising a total of $125.19M. The latest funding stage is Venture round.
Top alternatives and competitors to Bryn Pharma include ARS Pharmaceuticals, Inc., Windgap Medical, Inc., Portal Instruments, Neurelis, Inc., TheraJect, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Bryn Pharma and ARS Pharmaceuticals, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.
Source: BounceWatch company record for Bryn Pharma, https://bouncewatch.com/company/bryn-pharma, updated 2 December 2024. When citing, please name BounceWatch and link this page.
